References
- Peer D, Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett 2006; 237: 180–7
- Kaur P. Multidrug resistance: can different keys open the same lock?. Drug Resist Update 2002; 5: 61–4
- Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13–33
- Xu D, Lu Q, Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett 2006; 243: 274–80
- Kobayashi H, Takemura Y, Miyachi H. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics. Hum Cell 2001; 14: 172–84
- Motomura S, Motoji T, Takanashi M, et al. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 1998; 91: 3163–71
- Ramachandran C, Wellham LL. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Anticancer Res 2003; 23: 2681–90
- Ueda M, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance gene. J Biol Chem 1987; 262: 17432–8
- Callaghan R, Ford RC, Kerr ID. The translocation mechanism of P-glycoprotein. FEBS Lett 2006; 580: 1056–63
- Breier A, Barancik M, Sulova Z, et al. P-glycoprotein: implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005; 5: 457–68
- Xu D, Lu Q, Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett 2006; 243: 274–80
- Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156–9
- Gao P, Zhou GY, Zhang QH, et al. Reversal MDR in breast carcinoma cells by ribozyme designed according the secondary structure of mdr1 mRNA. Chin J Physiol 2006; 49: 96–103
- Sandhya T, Mishra KP. Cytotoxic response of breast cancer cell lines, MCF 7 and T 47 D to triphala and its modification by antioxidants. Cancer Lett 2006; 238: 304–13
- Fruehauf S, Breems D A, Knaan-Shanzer S, et al. Frequency analysis of multidrug resistency-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area forming cell assay and detection of vector-mediated p-glycoprotein expression by rhodamine 123. Hum Gene Ther 1996; 7: 1219–31
- Laible G, Wagner S, Alderson J. Oligonucleotide-mediated gene modification and its promise for animal agriculture. Gene 2006; 366: 17–26
- Thierry AR, Dritschilo A. Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells. Ann NY Acad Sci 1992; 660: 300–2
- Corrias MV, Tonini GP. An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res 1992; 12: 1431–8
- Quattrone A, Papucci L, Morganti M, et al. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol Res 1994; 6: 311–20
- Thierry AR, Rahman A, Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 1993; 190: 952–60
- Li J, Xu LZ, He KL, et al. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res 2001; 3: 253–63